Scott Struthers
Founder at CRINETICS PHARMACEUTICALS, INC.
Net worth: 49 M $ as of 2024-04-29
Scott Struthers active positions
Companies | Position | Start | End |
---|---|---|---|
CRINETICS PHARMACEUTICALS, INC. | Director/Board Member | 2008-10-31 | - |
Chief Executive Officer | 2008-11-30 | - | |
Founder | 2007-12-31 | - | |
President | 2008-11-30 | - | |
The San Diego Entrepreneurs Exchange | Director/Board Member | 2008-12-31 | - |
Founder | 2008-12-31 | - | |
Radionetics Oncology, Inc.
Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Chairman | 2021-09-30 | - |
Founder | 2021-09-30 | - |
Career history of Scott Struthers
Former positions of Scott Struthers
Companies | Position | Start | End |
---|---|---|---|
NEUROCRINE BIOSCIENCES, INC. | Director/Board Member | 1997-12-31 | 2007-12-31 |
Corporate Officer/Principal | 1997-12-31 | 2007-12-31 | |
ScienceMedia, Inc.
ScienceMedia, Inc. Electronics DistributorsDistribution Services ScienceMedia, Inc. provides marketing, communication, and e-learning solutions for life sciences and higher education markets. It offers solutions through the Web site and intranet, as well as through CD-ROMs. The company was founded by Arnold T. Hagler in 1995 and is headquartered in San Diego, CA. | Founder | 1994-12-31 | 1997-12-31 |
Training of Scott Struthers
University of California San Diego | Doctorate Degree |
Statistics
International
United States | 7 |
Operational
Founder | 4 |
Director/Board Member | 3 |
Chief Executive Officer | 1 |
Sectoral
Health Technology | 4 |
Distribution Services | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
CRINETICS PHARMACEUTICALS, INC. | Health Technology |
NEUROCRINE BIOSCIENCES, INC. | Health Technology |
Private companies | 3 |
---|---|
ScienceMedia, Inc.
ScienceMedia, Inc. Electronics DistributorsDistribution Services ScienceMedia, Inc. provides marketing, communication, and e-learning solutions for life sciences and higher education markets. It offers solutions through the Web site and intranet, as well as through CD-ROMs. The company was founded by Arnold T. Hagler in 1995 and is headquartered in San Diego, CA. | Distribution Services |
The San Diego Entrepreneurs Exchange | |
Radionetics Oncology, Inc.
Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Health Technology |
- Stock Market
- Insiders
- Scott Struthers
- Experience